Cryoablation
≈ 9 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Cryoablation is a process that uses extreme cold to destroy tissue. Cryoablation is performed using hollow needles (cryoprobes) through which cooled, thermally conductive fluids are circulated. Cryoprobes are positioned adjacent to the target in such a way that the freezing process will destroy the diseased tissue. Once the probes are in place, the attached cryogenic freezing unit removes heat from ("cools") the tip of the probe and by extension from the surrounding tissues. Ablation occurs in tissue that has been frozen by at least three mechanisms: # formation of ice crystals within cells thereby disrupting membranes, and interrupting cellular metabolism among other processes; # coagulation of blood thereby interrupting bloodflow to the tissue in turn causing ischemia and cell death; and # induction of apoptosis, the so-called programmed cell death cascade. The most common application of cryoablation is to ablate solid tumors found in the lung, liver, breast, kidney and prostate. The use in prostate and renal cryoablation are the most common. Although sometimes applied in cryosurgery through laparoscopic or open surgical approaches, most often cryoablation is performed percutaneously (through the skin and into the target tissue containing the tumor) by a medical specialist, such as an interventional radiologist. The term is from cryo- + ablation.…
Cryoablation is a process that uses extreme cold to destroy tissue. Cryoablation is performed using hollow needles (cryoprobes) through which cooled, thermally conductive fluids are circulated. Cryoprobes are positioned adjacent to the target in such a way that the freezing process will destroy the diseased tissue. Once the probes are in place, the attached cryogenic freezing unit removes heat from ("cools") the tip of the probe and by extension from the surrounding tissues. Ablation occurs in tissue that has been frozen by at least three mechanisms: formation of ice crystals within cells thereby disrupting membranes, and interrupting cellular metabolism among other processes; coagulation of blood thereby interrupting bloodflow to the tissue in turn causing ischemia and cell death; and induction of apoptosis, the so-called programmed cell death cascade. The most common application of cryoablation is to ablate solid tumors found in the lung, liver, breast, kidney and prostate. The use in prostate and renal cryoablation are the most common. Although sometimes applied in cryosurgery through laparoscopic or open surgical approaches, most often cryoablation is performed percutaneously (through the skin and into the target tissue containing the tumor) by a medical specialist, such as an interventional radiologist. The term is from cryo- + ablation. This offers distinct advantages and disadvantages when compared to other pain management modalities. Unlike chemical neurolysis (e.g., alcohol or phenol), cryoanalgesia is non-neurolytic and maintains the nerve's architectural integrity, facilitating regeneration and reducing the risk of deafferentation pain. Compared to radiofrequency ablation (RFA), cryoanalgesia often results in a less painful procedure and a lower incidence of neuroma formation. However, RFA may offer longer-lasting pain relief in some cases. Traditional local anesthetic nerve blocks provide immediate but short-lived relief, whereas cryoanalgesia provides extended pain control without permanent nerve destruction The equipment for cryoanalgesia typically consists of a cryoanalgesia unit (console) and specialized cryoprobes. The console regulates the flow of a cryogen (e.g., nitrous oxide or carbon dioxide gas) to the tip of the cryoprobe. Cryoprobes vary in size and design, featuring a small, insulated shaft and a uninsulated tip that forms an ice ball upon activation. Different probe sizes are chosen based on the target nerve's diameter and location. Cryoanalgesia is indicated for a wide range of chronic pain conditions where a temporary but prolonged nerve block is desired. Common indications include post-thoracotomy pain syndrome, intercostal neuralgia, trigeminal neuralgia (peripheral branches), occipital neuralgia, neuropathic pain following surgery or trauma, phantom limb pain, and pain associated with spasticity. It is also used for managing acute pain in certain surgical procedures, such as rib fractures or sternotomy.
Prostate
Prostate cryoablation is moderately effective but, as with any prostate removal process, also can result in impotence. Prostate cryoablation is used in three patient categories: as primary therapy in patients for whom sexual function is less important or who are poor candidates for radical retropubic prostatectomy (RRP, surgical removal of the prostate); as salvage therapy in patients who have failed brachytherapy (the use of implanted radioactive "seeds" placed within the prostate) or external beam radiation therapy (EBRT); and focal therapy for smaller, discrete tumors in younger patients.
Renal
Cryoablation has similar outcomes to radiofrequency ablation when treating renal cell carcinoma.
Breast cancer
Cryoablation for breast cancer is typically only possible for small tumors. Often surgery is used following cryoablation. As of 2014 more research is required before it can replace lumpectomy.
Cardiac
Another type of cryoablation is used to restore normal electrical conduction by freezing tissue or heart pathways that interfere with the normal distribution of the heart's electrical impulses. Cryoablation is used in two types of intervention for the treatment of arrhythmias: (1) catheter-based procedures and (2) surgical operations. A catheter is a very thin tube that is inserted into a vein in the patient's leg and threaded to the heart where it delivers energy to treat the patient's arrhythmia. In surgical procedures, a flexible probe is used directly on an exposed heart to apply the energy that interrupts the arrhythmia. By cooling the tip of a cryoablation catheter (cardiology) or probe (heart surgery) to sub-zero temperatures, the cells in the heart responsible for conducting the arrhythmia are altered so that they no longer conduct electrical impulses.
Fibroadenoma
Cryoablation is also currently being used to treat fibroadenomas of the breast. Fibroadenomas are benign breast tumors that are found in approximately 10% of women (primarily ages 15–30). In this procedure which has been approved by the U.S. Food and Drug Administration (FDA), an ultrasound-guided probe is inserted into the fibroadenoma and extremely cold temperatures are then used to destroy the abnormal cells. Over time the cells are reabsorbed into the body. The procedure can be performed in a doctor's office setting with local anesthesia and leaves very little scarring compared to open surgical procedures.
Cryoimmunotherapy
Cryoimmunotherapy is an oncological treatment for various cancers that combines cryoablation of tumor with immunotherapy treatment. In-vivo cryoablation of a tumor alone can induce an immunostimulatory, systemic anti-tumor response, resulting in a cancer vaccine – the abscopal effect. However, cryoablation alone may produce an insufficient immune response, depending on various factors, such as high freeze rate. Combining cryotherapy with immunotherapy enhances the immunostimulating response and has synergistic effects for cancer treatment.
History
The use of cold for pain relief and as an anti-inflammatory has been known since the time of Hippocrates (460–377 BC). Since then there have been numerous accounts of ice used for pain relief including from the Ancient Egyptians and Avicenna of Persia (AD 982–1070). Since 1899, Dr. Campbell White used refrigerants for treating a variety of conditions, including: lupus erythematosus, herpes zoster, chancroid, naevi, warts, varicose leg ulcers, carbuncles, carcinomas and epitheliomas. De Quervain successfully used of carbonic snow to treat bladder papillomas and bladder cancers in 1917. Dr. Irving S. Cooper, in 1913, progressed the field of cryotherapy by designing a liquid nitrogen probe capable of achieving temperatures of -196 °C, and utilizing it to treat of Parkinson's disease and previously inoperable cancer. Cooper's cryoprobe advanced the practice of cryotherapy, which led to growing interest and practice of cryotherapy. In 1964, Dr. Cahan successfully used his liquid nitrogen probe invention to treat uterine fibroids and cervical cancer. Cryotherapy continued to advance with Dr. Amoils developing a liquid nitrogen probe capable of achieving cooling expansion, in 1967. With the technological cryoprobe advancements in the 1960s came wider acceptance and practice of cryotherapy. Since the 1960s, liver, prostate, breast, bone, and other cancers have been treated with cryoablation in many parts of the world. Japanese physician Dr. Tanaka began treating metastatic breast cancer with cryoablation in 1968. For the next three decades, Dr. Tanaka successfully treated small and localized as well as advanced and unresectable breast cancer with minimally invasive cryoablation. All of Dr. Tanaka's breast cancer cases were considered incurable: advanced, unresectable, and resistant to radiotherapy, chemotherapy, and endocrine therapy. At the same time, physicians, including Dr. Ablin and Dr. Gage, started utilizing cryoablation for the treatment of prostate and bone cancer. Dr. Paul J. Wang MD and Dr. Peter L. Friedman MD, PhD invented cryoablation for the heart and cardiac arrhythmia in 1988. Their patents were for the cryoablation catheter and cryogenic mapping (US Patents 5147355A and 5423807A). The 1980s and 1990s saw dramatic advancement in apparatus and imaging techniques, with the introduction of CMS Cryoprobe, and Accuprobe. CT-, MRI-, and ultrasound-guided cryoprobes became available and improved the capabilities of cryoprobes in treatment. Excited by the latest advancements in cryotherapy, China embraced cryotherapy in the 1990s to treat many oncological conditions. With the benefits well-established, the FDA approved the treatment of prostate cancer with cryoablation in 19981.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371853122 under CC BY-SA 4.0; modifications have been made.
References
- ↩Wikipedia “Cryoablation” date of establishment (×1) · confidence 0.95 revision URL